Dr. Muss Discusses Evaluating Cardiac Toxicity in Patients With Breast Cancer

Hyman B. Muss, MD
Published Online: Monday, May 12, 2014
Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses evaluating cardiac toxicity in patients with breast cancer.

Oncologists are now used to doing echocardiograms, which do not require any isotopes and yield rich results, or multigated acquisition (MUGA) scans, which yield results as one simple number.

Muss hypothesizes that in 5-10 years, the best way to monitor cardiac toxicity may be with an MRI of the heart and that those who are researching heart MRI are seeing incredible results.




Online CME Activities
Free CME from PER
Advances in the Treatment of Metastatic Colorectal Cancer
Renal Cell Carcinoma: Recent Advances, New Questions
Community Practice Connections™: Working Group to Advance the Treatment of Triple-Negative Breast Cancer: Examining the Evidence and Looking to the Future
Community Practice Connections™: 10th Annual New York Lung Cancer Symposium®
More Reading
$auto_registration$